Race Oncology Board Renewal Update

Race Oncology Limited (ASX:RAC) has completed the first phase of its board renewal process, with the retirement of Non-Executive Chair, Ms Mary Harney, and Non-Executive Director, Mr Phil Lynch. Dr Pete Smith has been appointed as the Executive Chair, and Dr Daniel Tillett will now serve as the Managing Director & Chief Executive Officer. Additionally, Dr Serge Scrofani has joined Race as an Independent Non-Executive Director. The newly appointed board is designed to support the company through its next phase of development.

Executive Commentary on Board Renewal

Mary Harney, outgoing Non-Executive Chair, expressed gratitude for the time spent with Race and the significant advancements in the company's shape and strategy. Dr Pete Smith, Executive Chair, acknowledged the substantial growth and strengthening of the company during Mary and Phil's tenures. Dr Daniel Tillett, Managing Director & Chief Executive Officer, thanked Mary and Phil for their hard work and dedication, expressing a warm welcome to Serge as they focus on the significant commercial opportunity ahead. Dr Serge Scrofani, Non-Executive Director, expressed excitement in joining Race's Board and endorsed the company's innovative approach to developing cardioprotective cancer therapies.

Summary of Race Oncology Board Renewal

Race Oncology (ASX:RAC) has announced the completion of the first phase of its board renewal process, with the retirement of Ms Mary Harney and Mr Phil Lynch. Dr Pete Smith has been appointed as the Executive Chair, Dr Daniel Tillett as the Managing Director & Chief Executive Officer, and Dr Serge Scrofani as an Independent Non-Executive Director. The company expressed gratitude to the outgoing board members and welcomed the new appointments. The board renewal is aimed at supporting Race Oncology through its next phase of development. The company continues to focus on the significant commercial opportunity ahead, particularly in the development of cardioprotective cancer therapies. Race Oncology remains dedicated to being at the heart of cancer care and is actively exploring partnerships, license agreements, or a commercial merger and acquisition to accelerate access to bisantrene for cancer patients worldwide.